The IBD Research Study
Recruitment Closed
14 Aug 2026
Up to $11,400
Melbourne, Australia
The study drug is being developed to help people with inflammatory bowel disease (IBD). IBD causes ongoing inflammation in the digestive system and includes conditions like Crohn’s disease, ulcerative colitis, and indeterminate colitis. The study explains that there is still a real need for better treatments because current medicines don’t cure IBD, and many people either don’t respond well or stop responding over time.
Join our clinical trial
This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.
Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.
Why participate?
IBD is a longlasting condition:
Inflammatory bowel disease (IBD) doesn’t currently have a cure. Medicines can help control symptoms and reduce inflammation, but many people don’t get enough relief, or their treatment stops working over time.
IBD is becoming more common:
The number of people diagnosed with IBD has grown a lot worldwide—almost doubling between 1990 and 2021. It affects many people in Australia as well and places a big strain on individuals, families, and the healthcare system.
Better treatments are still needed:
Many people with IBD continue to have ongoing symptoms or develop complications such as a higher risk of certain cancers, low bone strength, anemia, or nutritional problems. Current medicines can also cause side effects. Because of this, there is a strong need for new treatments that address the underlying cause of IBD, not just its symptoms.
Trial details
Study duration
Total of 10 nights in Melbourne clinic split
across 10 short clinic stays, 4 follow-up visits
Study medication
Administered as an intravenous (IV) infusion
Additional eligibility requirements
- Carry HLA DRB40101 or DRB40103 gene
type - Non-smokers or smoking ≤2 per day or
≤10 per week
Ethics
The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee.
Are you a match?
Age
18 - 65 years old
Remuneration
Up to $11,400 *with screening reimbursement.
Full details outlined in consent form.
Gender
Male or Female
BMI
BMI 18 - 32 kg/m2
Commitment
Up to 10 nights, 4 clinic visits
Medical condition
Not taking any medications